Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, is set to present new data on its MDNA11 ABILITY-1 Trial at the Sachs 10th Annual Oncology Innovation Forum, coinciding with the 2024 ASCO Annual Meeting in Chicago. The update will cover the Phase 1/2 study results of MDNA11, a novel long-acting interleukin-2 super-agonist, demonstrating anti-tumor effects and safety profiles in advanced solid tumors. Additionally, Medicenna will discuss bizaxofusp, its Phase-3 ready immunotherapy for recurrent glioblastoma, at the same conference.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
